The Impact of Radiotherapy on Oligometastatic Cancer

Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.

NCT Number	NCT05933876
Lead Sponsor	Institut Investigacio Sanitaria Pere Virgili Collaborators: Hospital Ruber Internacional, Hospital Universitario Rey Juan Carlos, Quirón Madrid University Hospital, Hospital de La Luz, Institut Català d'Oncologia, Hospital Arnau de Vilanova, Hospital Universitari Sant Joan de Reus, Hospital Universitario Virgen Macarena, Hospital Universitario Reina Sofia de Cordoba, Hospital General Universitario de Valencia, Hospital Clínico Universitario de Valencia, Complejo Hospitalario Universitario de Albacete, Hospital de Terrassa, Hospital Universitario Ramon y Cajal, Hospital del Mar, Hospital Provincial de Castellon, Hospital de la Santa creu i Sant Pau - Barcelona, HM Sanchinarro University Hospital, Hospital Miguel Servet, University Hospital Virgen de las Nieves, Hospital Vall d'Hebron
Conditions	Metastasis, Metastatic Breast Cancer, Metastatic Prostate Cancer, Metastatic Colorectal Cancer, Metastatic Lung Cancer
Enrollment	2,000 participants
Start Date	2022-12-01
Primary Completion	2037-12-31 (estimated)
Study Completion	2037-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-11-18